by Indigo | Feb 21, 2023 | 2023, News, Press
BELGIUM – Ghent, 21 February 2023: Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of Continuous Metabolite Monitoring (CMM®) devices utilising proprietary nanophotonics technology, today announces that that an abstract featuring its CMM®...
by Indigo | Jan 4, 2023 | 2023, News, Press
SHINE clinical trial enrolment progressing well following positive results from the GLOW early feasibility trial Several key senior appointments made in Europe and the US, reflecting the growth and evolution from an early stage to a development stage...
by Indigo | Oct 27, 2022 | 2022, News, Press
Indigo establishes a US presence to drive business development and extend talent acquisition Peter brings over 30 years’ experience leading the development & commercialisation of medical devices, including devices for the diabetes market Ghent, 27 October...
by Indigo | Sep 29, 2022 | 2022, News
indigo diabetes announces first participant enrolled in the shine clinical trial BELGIUM – Ghent, September 29, 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today announces the enrollment of...
by Indigo | Sep 9, 2022 | 2022, News
We are pleased to announce the appointment of Mike Malecha as VP Digital Will lead the development of software digital strategies, ensuring compliant and secure data management for Indigo’s continuous metabolite monitoring device Brings over 15 years’ experience...
by Indigo | May 10, 2022 | 2022, News
We are pleased to announce the appointment of Emmet Lydon as Chief Operating Officer BELGIUM – Ghent, 10 May 2022 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today announces the appointment of...
